Pasithea Therapeutics Corp. (KTTA): Total Assets
$60.24M
As of 2025-12-31
$51.71M
As of 2026-06-30
+10.1%
3-year compound annual growth
n/m
5-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $60.24M | +275.0% | 2026-03-30, Balance as of period end |
| 2024-12-31 | $16.06M | -38.5% | 2026-03-30, Balance as of period end |
| 2023-12-31 | $26.12M | -42.2% | 2025-03-24, Balance as of period end |
| 2022-12-31 | $45.18M | -15.3% | 2024-03-29, Balance as of period end |
| 2021-12-31 | $53.32M | n/m | 2023-03-30, Balance as of period end |
| 2020-12-31 | $248.0K | n/a | 2022-03-30, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Pasithea Therapeutics Corp. (KTTA) | 2025-12-31 | $60.24M | +275.0% |
| ProPhase Labs, Inc. (PRPH) | 2025-12-31 | $59.87M | -5.3% |
| Palvella Therapeutics, Inc. (PVLA) | 2025-12-31 | $59.56M | -32.5% |
| DiaMedica Therapeutics Inc. (DMAC) | 2025-12-31 | $61.37M | +32.4% |
| ALX Oncology Holdings Inc (ALXO) | 2025-12-31 | $59.05M | -60.0% |
| Scynexis Inc (SCYX) | 2025-12-31 | $59.03M | -34.9% |
| Q32 Bio Inc. (QTTB) | 2025-12-31 | $61.78M | -33.1% |
| Rani Therapeutics Holdings, Inc. (RANI) | 2025-12-31 | $58.62M | +60.0% |
| AN2 Therapeutics, Inc. (ANTX) | 2025-12-31 | $61.95M | -32.7% |
Compare KTTA, PRPH, PVLA, DMAC side by side · Screen every company in Pharmaceutical Preparations ↗